Search Results
Dr. Tripathy on Trastuzumab Deruxtecan Versus T-DM1 in HER2-Expressing Breast Cancers
T-DM1 Vs. Trastuzumab as Adjuvant Therapy for HER2-Positive Breast Cancer
Trastuzumab deruxtecan: a promising agent for treating HER2-low breast cancer?
Phase 3 Trial Investigates T-DM1 and Pertuzumab in HER2+ Breast Cancer
Dr. Cheng on the Role of T-DM1 in HER2+ Breast Cancer
Trastuzumab Emtansine in HER2+ Breast Cancer
Case Review: T-DM1 for Residual HER2+ Breast Cancer
New Breast Cancer Clinical Trial: Trastuzumab Deruxtecan for Breast Cancer
Trastuzumab Deruxtecan for HER2-Mutated Metastatic NSCLC
Dr. Pegram on Early Treatment With T-DM1
Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trastuzumab and ET in...
Dr. Dang on the DESTINY-Breast01 Trial in HER2+ Metastatic Breast Cancer
